Orion Corporation: Managers’ Transactions Report
Orion Corporation has released information in accordance with the Market Abuse Regulation (EU) No 596/2014, which outlines transactions involving shares and linked securities carried out by managers and those closely associated with them.
Details of the Transaction
This transaction notification concerns Satu Ahomäki, who serves as an Other Senior Manager at Orion Corporation. The initial notification is documented under reference number 75121/4/4.
Transaction Summary
The transaction took place on August 21. All activities were executed at NASDAQ HELSINKI LTD (XHEL) and involved shares of Orion Corporation, identified by the ISIN code FI0009014377.
Nature and Details of Transactions
The transactions primarily involved disposals, with multiple entries reported. In total, there were 84 transactions executed, each varying in volume and price as outlined below:
Transaction details show volumes ranging from 1 to 267 shares, with unit prices fluctuating between 46.75 EUR and 46.81 EUR.
When aggregated, these transactions account for a total volume of 5000 shares, with a volume-weighted average price of 46.75959 EUR.
About Orion Corporation
Orion Corporation is a well-established Finnish pharmaceutical company that has been making significant contributions to healthcare for over a century. The company specializes in the development, manufacturing, and marketing of both human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients.
Core Areas of Focus
Orion boasts a diverse portfolio that includes both proprietary and generic medicines, along with consumer health products. Their research and development efforts are primarily directed towards oncology and pain management.
Market Position and Performance
Orion's proprietary products are widely used for treating various health conditions, including cancer, neurological disorders, and respiratory diseases. The company's net sales for the year reached EUR 1,190 million, and it employed around 3,600 individuals at the end of the year.
Leadership Team
The leadership team at Orion Corporation includes:
- Liisa Hurme - President and CEO
- Olli Huotari - SVP, Corporate Functions
Contact Information
For additional inquiries, please reach out to:
Orion Corporation Communications
Orionintie 1A, FI-02200 Espoo, Finland
Frequently Asked Questions
1. What is the significance of the managers' transactions report?
This report enhances transparency regarding trading activities conducted by management, ensuring compliance with regulatory standards to maintain market integrity.
2. How many transactions did Satu Ahomäki execute?
Satu Ahomäki completed a total of 84 transactions involving share disposals during the specified timeframe.
3. What was the average price of shares disposed of in these transactions?
The average price for the disposed shares, calculated as a volume-weighted average, was 46.75959 EUR.
4. What areas does Orion Corporation focus on in its R&D?
Orion's research and development primarily target oncology and pain management in the pharmaceutical sector.
5. How can one contact Orion Corporation for more information?
For more information, Orion Corporation can be contacted through their communications office located at Orionintie 1A, FI-02200 Espoo, Finland.
